Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -7.58 is 90% above its 5-year average of -76.67, near the high end of its 5-year range (-123.27–-7.58).
80.56% above its 12-month average of -39.00.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.74.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-7.58
EARNINGS PER SHARE (EPS) AVG TTM
-39.00
EARNINGS PER SHARE (EPS) AVG 3Y
-56.28
EARNINGS PER SHARE (EPS) AVG 5Y
-76.67
EARNINGS PER SHARE (EPS) AVG 10Y
-94.68
EARNINGS PER SHARE (EPS) AVG 15Y
-95.26
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+80.56%
CURRENT VS 3Y AVG
+86.53%
CURRENT VS 5Y AVG
+90.11%
CURRENT VS 10Y AVG
+91.99%
CURRENT VS 15Y AVG
+92.04%
CURRENT VS 20Y AVG
N/A
Crescent Biopharma, Inc.
Market Cap
$522.80M
Earnings Per Share (EPS)
-7.58
TTM Avg
-39.00
3Y Avg
-56.28
5Y Avg
-76.67
Market Cap
$523.00M
Earnings Per Share (EPS)
-2.34
TTM Avg
-1.60
3Y Avg
-1.16
5Y Avg
-0.99
Market Cap
$520.22M
Earnings Per Share (EPS)
-0.78
TTM Avg
-1.17
3Y Avg
-1.45
5Y Avg
-1.68
Market Cap
$534.01M
Earnings Per Share (EPS)
-0.88
TTM Avg
-0.82
3Y Avg
-0.78
5Y Avg
-1.65
Market Cap
$509.64M
Earnings Per Share (EPS)
-0.95
TTM Avg
-1.56
3Y Avg
-1.33
5Y Avg
-1.41
Market Cap
$536.32M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.57
3Y Avg
-0.87
5Y Avg
-0.89
Market Cap
$539.40M
Earnings Per Share (EPS)
0.01
TTM Avg
0.08
3Y Avg
-2.02
5Y Avg
-4.00
Market Cap
$503.89M
Earnings Per Share (EPS)
-0.67
TTM Avg
-1.09
3Y Avg
-1.67
5Y Avg
-1.68
Market Cap
$542.17M
Earnings Per Share (EPS)
-1.28
TTM Avg
-4.16
3Y Avg
-4.49
5Y Avg
-4.33
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $522.80M | -7.58 | -39.00 | -56.28 | -76.67 |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.00M | -2.34 | -1.60 | -1.16 | -0.99 |
| Altimmune, Inc. (ALT)vs › | $520.22M | -0.78 | -1.17 | -1.45 | -1.68 |
| Immix Biopharma, Inc. (IMMX)vs › | $534.01M | -0.88 | -0.82 | -0.78 | -1.65 |
| 908 Devices Inc. (MASS)vs › | $509.64M | -0.95 | -1.56 | -1.33 | -1.41 |
| ProKidney Corp. (PROK)vs › | $536.32M | -0.57 | -0.57 | -0.87 | -0.89 |
| Delcath Systems, Inc. (DCTH)vs › | $539.40M | 0.01 | 0.08 | -2.02 | -4.00 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.89M | -0.67 | -1.09 | -1.67 | -1.68 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.17M | -1.28 | -4.16 | -4.49 | -4.33 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $549.34M | N/A | -1.57 | -1.57 | -1.57 |
Trailing EPS (TTM)
$-7.58
Forward EPS (Est.)
$-3.08
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -14.78 |
| 2024-12-31 | -63.22 |
| 2023-12-31 | -58.25 |
| 2022-12-31 | -88.88 |
| 2021-12-31 | -123.27 |
| 2020-12-31 | -111.60 |
| 2019-12-31 | -133.84 |
| 2018-12-31 | -117.61 |
| 2017-12-31 | -113.22 |
| 2016-12-31 | -149.65 |
| 2015-12-31 | -67.17 |
| 2014-12-31 | -60.27 |
| 2013-12-31 | -199.32 |
| 2012-12-31 | 305.64 |
| 2011-12-31 | -32.55 |
